Avastin eye injection is a treatment for macular degeneration and other eye diseases
Macular degeneration is the leading cause of blindness in people over the age of 50. Avastin can slow or stop vision robbing leaking and swelling (wet macular degeneration) in the retina.
The macula is the highly sensitive part of the retina, on the back of your eye. Vision works like the film in a camera by picking up the picture being focused by your cornea and eye’s lens. Macular degeneration occurs when there is a breakdown of the macula, in the central portion of the retina. Since the macula is responsible for the fine central vision in the eye that is needed for driving a car, reading fine print, recognizing faces, etc., central blindness can occur.
There are two types of macular degeneration: dry and wet macular degeneration. In the wet form of AMD, abnormal blood vessels grow in the back of the eye. Sometimes these vessels leak blood or fluid that causes blurred vision or distorted vision. Without treatment, vision loss may be quick and severe.
the patient should consult their retina specialist / ophthalmologist about signs and symptoms of Avastin side effects.
Avastin is an eye injection drug given by an eye surgeon. It is better and more effective than traditional laser eye surgery because it does not leave scarring in the macular central portion of vision.
Avastin was developed by Genentech for colorectal cancer and is not FDA approved for ARMD, although it is widely used for wet macular degeneration.
Avastin side effects
For the Avastin dose recommended for colorectal cancer, there are many possible side effects. Avastin for treatment of macular degeneration however, there are very few and rare side effects. The possibility of infection is extremely important to understand and the patient should consult their retina specialist / ophthalmologist about signs and symptoms of Avastin side effects.
Avastin eye injection uses
Avastin has also been approved for the treatment of diabetic macular edema and retinal vein occlusion.